Exanta Oral & Sub-Q Cleared In France; U.S. NDA Seeks Oral Formulation Only
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Proposed European labeling for AstraZeneca’s anticoagulant Exanta does not call for regular liver monitoring.